Roche Diagnostics announced that the US Food & Drug Administration (FDA) today approved its biologics license application for the company's test for direct detection of West Nile Virus in donated human blood and plasma.
West Nile virus, which can cause serious health issues, is transmitted to humans most often through mosquito bites, but can also less commonly be transmitted by transfusion of infected blood or blood products.
The test, called the cobas TaqScreen West Nile Virus Test, enables detection of the virus earlier in the infection cycle in donors who may show no symptoms of disease. According to the CDC, blood screening centers across the United States identified 340 donors whose blood tested positive for West Nile Virus in 2006 and 23 to date in 2007.
"We are pleased to offer US blood banks a new choice for both maximizing blood safety and optimizing efficiency," said Daniel O'Day, Head of Roche Molecular Diagnostics, the business area of Roche Diagnostics which developed the test.
"The Roche test, run under an investigational new drug application by 14 clinical trial sites testing blood from a network of more than a 100 donation centers, helps blood banks streamline workflow and improve test results accuracy with reduced hands-on time, ready-to-use reagents, and full automation of each step."
The test is designed to run on the cobas s 201 system, Roche's flexible, modular instrument platform which automates each step of the real-time PCR blood screening process.
The test uses Roche's polymerase chain reaction technology (PCR), the nucleic acid amplification technology, to detect the genetic material of the West Nile virus directly in blood.
The United States Centers for Disease Control (CDC) has stated that screening donated blood for West Nile Virus by nucleic acid amplification tests has markedly reduced the risk of transfusion transmission.